Form 4: Viridian Therapeutics Director Arlene Morris Granted 21,000 Stock Options

Viridian Therapeutics, Inc. Director Arlene Morris was granted 21,000 stock options with an exercise price of $14.47, vesting by July 2026.

Summary

• Arlene Morris, a Director of Viridian Therapeutics, Inc. (VRDN), was granted 21,000 stock options on July 1, 2025.
• The stock options have an exercise price of $14.47 per share.
• Each option represents the right to buy one share of Viridian Therapeutics Common Stock.
• The options will vest in full upon the earlier of July 1, 2026, or the Issuer's 2026 annual meeting of stockholders.
• Vesting is contingent upon Ms. Morris's continued service on the Board of Directors.
• The stock options have an expiration date of July 1, 2035.
• Following this transaction, Arlene Morris beneficially owns 21,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard practice for aligning interests and retaining talent, generally viewed as a neutral to slightly positive event for corporate governance and long-term incentive alignment.

Positives

• The grant of stock options aligns the financial interests of Director Arlene Morris with those of the shareholders, incentivizing long-term company performance.

Future Outlook

The granted stock options are set to vest in full by July 1, 2026, or the 2026 annual meeting, subject to the director's continued service on the Board of Directors.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries to align leadership incentives with long-term company performance and shareholder value. This type of equity compensation is a standard component of director remuneration packages.

Comparison to Industry Standards

• Equity compensation for directors, such as stock options, is a standard practice across publicly traded companies, including those in the biotechnology sector like Viridian Therapeutics, to align board member interests with shareholder value.
• The vesting schedule, which ties full vesting to continued service and a specific future date or event (2026 annual meeting), is typical for director equity grants, aiming to retain experienced board members.
• The exercise price being set at the market price on the grant date (implied by the $0 value for the option itself in the table and the specified exercise price of $14.47) is standard for non-qualified stock options granted to directors.

Corporate Governance

Related Party Transactions

• Grant of 21,000 stock options to Arlene Morris, a Director of Viridian Therapeutics, Inc., with an exercise price of $14.47 per share, as part of her compensation.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also improved alignment of the director's interests with long-term shareholder value.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Continued service of Arlene Morris on the Board of Directors of Viridian Therapeutics, Inc.
• Vesting of the 21,000 stock options by July 1, 2026, or the 2026 annual meeting of stockholders.
• Potential exercise of the vested stock options by Arlene Morris before their expiration date of July 1, 2035.

Key Dates

Recommendation

Keywords

Viridian Therapeutics, VRDN, Stock Option, Director Compensation, Equity Grant, SEC Form 4, Insider Transaction, Corporate Governance